Biomea Fusion to Present Late Breaking Data from Ongoing Phase II Trial, COVALENT-111, Evaluating BMF-219 in Patients with Type 2 Diabetes, at the ADA 83rd Scientific Sessions 2023 in June
19 avr. 2023 08h30 HE
|
Biomea Fusion, Inc.
New clinical data from COVALENT-111 will be featured during the Late-Breaking Poster Presentations at the Scientific SessionsBiomea to hold an investor and KOL event during the Scientific Sessions ...
Biomea Fusion To Present Two Preclinical Posters at the 114th AACR Annual Meeting
13 avr. 2023 16h30 HE
|
Biomea Fusion, Inc.
Abstract 473 highlights the dose dependent reduction of menin target genes in ex vivo chronic lymphocytic leukemia (CLL) patient samples treated with BMF-219, an investigational covalent inhibitor....
Biomea Fusion Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
13 avr. 2023 09h00 HE
|
Biomea Fusion, Inc.
REDWOOD CITY, Calif., April 13, 2023 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and...
Biomea Fusion Announces Pricing of Upsized Public Offering of Common Stock
29 mars 2023 23h15 HE
|
Biomea Fusion, Inc.
REDWOOD CITY, Calif., March 29, 2023 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel...
Biomea Fusion Announces Proposed Public Offering of Common Stock
29 mars 2023 06h30 HE
|
Biomea Fusion, Inc.
REDWOOD CITY, Calif., March 29, 2023 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel...
Biomea Fusion Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights
28 mars 2023 16h02 HE
|
Biomea Fusion, Inc.
Expanded clinical development footprint of BMF-219, the company’s lead investigational, orally administered, covalent menin inhibitor, to eight liquid and solid tumor indications and type 2 diabetes...
Biomea Fusion Announces Positive Data from Initial Cohorts of Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes; 100 mg Cohort 3 Demonstrated an 89% Response Rate and 1% Median Reduction in HbA1c at Day 28
28 mars 2023 08h00 HE
|
Biomea Fusion, Inc.
In Cohort 3, after 4 weeks of once-daily 100 mg dosing with the investigational, oral covalent menin inhibitor, BMF-219, 89% of patients achieved a reduction in A1c, 78% of patients achieved at least...
Biomea Fusion to Host Conference Call and Webcast to Discuss Initial Phase II Clinical Data for BMF-219 in Subjects with Type 2 Diabetes on March 28th, 2023 at 8:30 a.m. ET
23 mars 2023 08h00 HE
|
Biomea Fusion, Inc.
REDWOOD CITY, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel...
Biomea Fusion To Participate In Upcoming Investor Events
02 mars 2023 08h30 HE
|
Biomea Fusion, Inc.
REDWOOD CITY, Calif., March 02, 2023 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a biopharmaceutical company focused on the discovery and development of covalent small...
Biomea Fusion Doses First Patient in Phase I/Ib Clinical Trial (COVALENT-102) of BMF-219 in KRAS Mutant Solid Tumors
17 janv. 2023 08h00 HE
|
Biomea Fusion, Inc.
BMF-219 is the first menin inhibitor to be clinically studied in patients with KRAS-mutated non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC)A...